Innate Pharma has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. The collaboration is to evaluate the combination of Innate Pharma's first-in-class IPH5401 antibody and Imfinzi (durvalumab) in a Phase I/II study for patients with selected solid tumors.
The Phase I/II study (STELLAR-001) will evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with Innate's investigational first-in-class anti-C5aR monoclonal antibody, IPH5401, as a treatment for patients with selected solid tumors.
"Our collaboration with MedImmune provides further evidence of Innate's commitment to exploring the full combination potential of IPH5401 as we progress our immuno-oncology portfolio," said Mondher Mahjoubi, chief executive officer of Innate Pharma. "We believe IPH5401 could become an important partner in PD-1/PD-L1 combination strategies."
The Phase I part of the trial is expected to establish a recommended dose regimen of IPH5401 in combination with durvalumab in selected solid tumors, and the Phase II part will assess the safety and efficacy of the combination in these patients. The study will be conducted by Innate and the costs will be equally shared by both parties. The agreement between Innate Pharma and MedImmune is non-exclusive.
Both durvalumab and IPH5401 are cancer immunotherapies, a potent class of treatments that use the body's own immune system to help fight cancer.